Human genetic studies have implicated the voltage-gated sodium channel NaV1.7 as a therapeutic target for the treatment of pain. A novel peptide, μ-theraphotoxin-Pn3a, isolated from venom of the tarantula Pamphobeteus nigricolor, potently inhibits NaV1.7 (IC50 0.9 nM) with at least 40–1000-fold selectivity over all other NaV subtypes. Despite on-target activity in small-diameter dorsal root ganglia, spinal slices, and in a mouse model of pain induced by NaV1.7 activation, Pn3a alone displayed no analgesic activity in formalin-, carrageenan- or FCA-induced pain in rodents when administered systemically. A broad lack of analgesic activity was also found for the selective NaV1.7 inhibitors PF-04856264 and phlotoxin 1. However, when administered with subtherapeutic doses of opioids or the enkephalinase inhibitor thiorphan, these subtype-selective NaV1.7 inhibitors produced profound analgesia. Our results suggest that in these inflammatory models, acute administration of peripherally restricted NaV1.7 inhibitors can only produce analgesia when administered in combination with an opioid.
The pore-forming subunits of voltage-gated sodium channels (NaV) are integral membrane proteins that allow influx of sodium ions, which is essential for action potential generation and propagation in electrically excitable cells. They are comprised of four homologous but non-identical domains (DI–IV), each consisting of six α-helical transmembrane segments (S1–S6) connected by multiple intracellular and extracellular loops1,2. The channels are composed of two functionally distinct components: the S1–S4 transmembrane segments form the voltage-sensing domain that undergoes a conformational change in response to changes in membrane potential in order to initiate channel opening, while the S5–S6 segments form the pore region that controls ion selectivity and allows sodium influx. Mammals express nine NaV channel subtypes (NaV1.1–1.9) that have distinct expression profiles and biophysical and pharmacological characteristics, with compelling genetic evidence linking NaV1.7 to pain1.
Loss-of-function mutations in SCN9A, the gene encoding NaV1.7, have been identified as a cause of congenital insensitivity to pain (CIP), a rare condition characterized by the inability to sense pain in individuals that are otherwise normal aside from anosmia (absence of sense of smell)3,4. Gain-of-function mutations of SCN9A are the cause of two hereditary pain disorders, inherited erythromelalgia (IEM) and paroxysmal extreme pain disorder (PEPD)5,6,7. Both disorders are associated with redness, swelling and burning pain, limited to the extremities in IEM and to the rectal, ocular and mandibular areas in PEPD. Therefore, pharmacological inhibition of NaV1.7 appears to be a promising therapeutic strategy for the treatment of pain. Developing analgesics with NaV1.7 selectivity is essential, as activity at the skeletal muscle isoform NaV1.4, the cardiac isoform NaV1.5, and the neuronal isoforms NaV1.1, NaV1.2 and NaV1.6 are likely to cause dose-limiting adverse effects8,9,10.
However, efforts to develop selective small molecule inhibitors have been hampered due to the high sequence identity (>50%) between NaV subtypes, particularly in the pore forming segments (S5–S6) where local anaesthetics bind. Although some small molecule inhibitors of NaV1.7 that target the voltage-sensing domain have been described, the in vivo efficacy of these compounds in inflammatory and neuropathic pain animal models has not been reported11,12. We therefore know surprisingly little about the therapeutic potential of highly selective NaV1.7 inhibitors.
Spiders have evolved pharmacologically complex venoms dominated by disulfide-rich peptides, many of which act at ion channels to rapidly immobilise prey or deter predators13,14. Insect and vertebrate NaV channel share 55–60% sequence identity and consequently many spider venom-derived peptides act on mammalian NaV channels15,16,17. These venom peptides typically bind to the less conserved voltage-sensing domains, and hence they often achieve much better subtype selectivity than small molecules that bind to the pore region of the channel14,18.
Here, we report the isolation and characterization of μ-TRTX-Pn3a, a peptide isolated from venom of the South American tarantula Pamphobeteus nigricolor, and show that it has exquisite selectivity for NaV1.7. Using Pn3a, as well as the small molecule NaV1.7 inhibitor PF-04856264 and the spider venom peptide phlotoxin 111,19,20, we assessed the therapeutic potential of selective NaV1.7 inhibition in multiple in vivo rodent models of pain. Surprisingly, despite on-target activity in vivo, these selective NaV1.7 inhibitors lacked analgesic activity in formalin-, carrageenan- and Freund’s complete adjuvant-induced pain models when administered alone. However, supporting the recently described crucial contribution of opioids to the NaV1.7 loss-of-function pain-free phenotype21, co-administration with a sub-effective dose of the opioids oxycodone or buprenorphine or the enkephalinase inhibitor thiorphan yielded analgesia, while co-administration with gabapentin had no effect. These results highlight the lack of broad analgesic efficacy in rodent models of pain with these peripherally restricted selective NaV1.7 inhibitors and confirm the proposed analgesic synergy between selective NaV1.7 inhibitors and opioids suggested by a recent study21.
Isolation of the novel spider venom peptide μ-TRTX-Pn3a from Pamphobeteus nigricolor
Crude venom isolated from Pamphobeteus nigricolor (Fig. 1a) partially inhibited veratridine-induced membrane potential changes in HEK293 cells stably expressing rNaV1.3, with activity-guided fractionation isolating this activity to a single peak with a retention time of 38 min (Fig. 1b). Matrix assisted laser desorption/ionization time-of-flight mas spectrometry (MALDI-TOF MS) of this fraction revealed two dominant masses corresponding to monoisotopic masses of 4210.5 and 4268.5 Da. N-terminal sequencing identified two novel 35-residue sequences differing only by the N-terminal amino acid (Fig. 1c) that we named μ-TRTX-Pn3a (hereafter Pn3a) and μ-TRTX-Pn3b based upon the revised nomenclature recently proposed for spider-venom peptides22. We subsequently chose to investigate Pn3a, as this was the major sequence identified by the N-terminal sequencing. Chemical synthesis of Pn3a produced the correctly folded product, as native and synthetic Pn3a co-eluted when assessed using analytical HPLC (data not shown). Synthetic Pn3a was used for all further experiments.
Pn3a is a potent and selective inhibitor of NaV1.7
Detailed subtype selectivity characterization using whole cell electrophysiology in HEK293 cells revealed that Pn3a most potently inhibits hNaV1.7 (pIC50 9.06 ± 0.08 M), with 40-fold selectivity over hNaV1.1 (pIC50 7.43 ± 0.06 M), 100-fold selectivity over hNaV1.2 (pIC50 6.91 ± 0.07 M), hNaV1.3 (pIC50 6.68 ± 0.08 M), hNaV1.4 (pIC50 6.84 ± 0.08 M) and hNaV1.6 (pIC50 6.89 ± 0.05 M), and greater than 900-fold selectivity over the tetrodotoxin (TTX)-resistant subtypes hNaV1.5 (pIC50 6.10 ± 0.06 M), hNaV1.8 (pIC50 4.30 ± 0.09 M), and hNaV1.9 (pIC50 5.62 ± 0.11 M), making Pn3a one of the most selective NaV1.7 inhibitors reported to date (Fig. 2a,b and see Table 1 for IC50 values). Pn3a inhibited mouse NaV1.7 (pIC50 8.36 ± 0.11 M) and rat NaV1.7 (pIC50 8.83 ± 0.18 M) with similar potency to human NaV1.7, which is important for pre-clinical in vivo studies performed in rodents (see Table 1 for IC50 values). At a concentration that nearly abolished inward current at NaV1.7, Pn3a (10 nM) had little effect on the current traces for other NaV isoforms, with the exception of enhancing inactivation at NaV1.1 and slowing the inactivation time constant at NaV1.8 (Fig. 2c). We also assessed the effects of Pn3a at selected off-targets, including voltage-gated potassium (KV) channels, voltage gated calcium (CaV) channels and nicotinic acetylcholine receptors (nAChRs). Pn3a had no significant effect at rKV2.1 up to 300 nM (see below) or on hCaV1.2, hCaV2.2, α7 nAChR or α3 nAChR up to 10 μM (data not shown).
Pn3a is a gating modifier toxin that alters the voltage-dependence of NaV1.7 activation
In general, spider venom-derived peptides bind to the voltage-sensing domains of NaV channels to modify gating associated with channel activation and inactivation14. We thus examined the effect of Pn3a on the current-voltage (I-V) relationship as well as the voltage-dependence of activation and steady-state fast inactivation on NaV1.1–1.8 (Fig. 3). With NaV1.7, Pn3a had a slow onset of effect, with time constants of block of 23 s, 167 s and 780 s for concentrations of 100 nM, 30 nM and 10 nM, respectively (Fig. 4a). Interestingly, this slow onset of effect was only observed for NaV1.7 and is similar to that reported for the NaV1.7 selective spider peptide ProTx-II23. Long application times required to reach steady-state inhibition precluded testing Pn3a at lower concentrations and we thus examined the effects of 100 nM Pn3a on NaV1.1–1.8.
At NaV1.7, Pn3a (Fig. 3) shifted the voltage-dependence of activation to more depolarized membrane potentials (V1/2 activation: Δ = +21.3 mV), confirming gating modifier activity. Interestingly, this effect on the voltage-dependence of activation was unique to NaV1.7, with Pn3a (100 nM) causing no significant effect on the V1/2 of activation at other NaV subtypes (Fig. 3 and Table 2). Minor effects were observed for Pn3a (100 nM) on the voltage-dependence of steady-state fast inactivation for NaV1.7 (V1/2 inactivation: Δ = −2.7 mV) as well as NaV1.1, 1.2, 1.3, 1.4 and 1.8 (Fig. 3 and Table 2).
To investigate the effects of Pn3a on the kinetics of activation and fast inactivation, we measured time-to-peak and the time constants of fast inactivation at NaV1.7. Pn3a (100 nM) significantly slowed the time-to-peak between −10 mV and 15 mV (P < 0.05, two-way ANOVA; Fig. 4b) and voltage-dependently slowed the inactivation time constants between −10 mV and 0 mV (P < 0.05, two-way ANOVA; Fig. 4c). Pn3a (100 nM) also significantly slowed recovery from fast inactivation at NaV1.7 (control, τ = 3.98 ms; Pn3a, τ = 8.77 ms; P < 0.05; paired t-test;), confirming reduced availability of toxin-bound NaV1.7 channels for re-activation suggested by the toxin effects on steady-state fast inactivation (Fig. 4d). In addition to fast inactivation, NaV1.7 channels can inactivate by slow inactivation, a process that occurs over seconds (as opposed to milliseconds) and results in a different conformational state. Pn3a (100 nM) had no effect on the voltage-dependence of steady-state slow inactivation, causing no significant shift in the V1/2 of slow inactivation (control, −50.5 ± 1.4 mV; Pn3a, −55.9 ± 2.9 mV; P > 0.05; paired t-test; Fig. 4e) and had no preference for the slow-inactivated state (data not shown). This is in contrast to the NaV1.7 selective small molecule inhibitor PF-04856264 and clinical lead PF-05089771, which both preferentially bind to the slow inactivated state11,24.
An important biophysical property of NaV1.7 is the ability to produce currents in response to small, slow depolarization ramps25. Pn3a (100 nM) completely inhibited NaV1.7 ramp currents elicited by a 50-ms depolarization from −100 to +20 mV (2.4 mV/ms) (Fig. 4f), indicating that it should inhibit NaV1.7-mediated generator currents at sensory nerve endings.
Pn3a binds to DII and DIV of NaV1.7
To determine the Pn3a binding site on hNaV1.7, we assessed the effects of Pn3a on hNaV1.7/KV2.1 channel chimeras, where the S3-S4 linker from each domain of hNaV1.7 is inserted into the homotetrameric KV2.1 channel26. Pn3a (300 nM) had no effect on wild-type KV2.1, but inhibited potassium currents in the DII hNaV1.7/KV2.1 and DIV hNaV1.7/KV2.1 chimeras, indicating that Pn3a interacts with the S3-S4 linkers in both of these domains (Fig. 4g). This is consistent with the demonstration that interaction of NaV channel toxins with any of the voltage-sensing domains I–III affect channel activation, whereas inactivation is only affected by toxins that bind exclusively to voltage-sensing domain IV27. Moreover, despite interactions with the DIV voltage-sensing domain, Pn3a potency was not significantly reduced in the hNaV1.7 M123 mutant (Y1537S/W1538R/D1586E) expressed in HEK293 cells (data not shown), indicating that Pn3a does not overlap with the binding site of the NaV1.7 selective small molecule inhibitor PF-0485626411.
Solution structure of Pn3a
The three-dimensional solution structure of Pn3a was determined using 2D homonuclear NMR spectroscopy. The NMR data were of excellent quality with sharp and well-dispersed resonances, consistent with a single well-ordered structure in solution. NMR-derived interproton distances, hydrogen bonds and dihedral angles were used for structure calculations with simulated annealing and subsequent water minimization28. The ensemble of 20 conformations representing the solution structure of Pn3a is shown in Fig. 5a (Protein Data Bank code 5T4R) and the structural statistics presented in Supplementary Table 1. Pn3a forms an inhibitor cysteine knot (ICK) fold that is common in spider-venom peptides. The ICK motif provides rigidity to the peptide, with the only backbone flexibility observed at the termini (Fig. 5a). An anti-parallel β-sheet is formed between β-strands I (K19-K22) and II (R27-R27) that are connected by four tight turns (Fig. 5b). The β-sheet structure correlated with observed NOE peaks and predicted hydrogen bonding patterns and is a common structural element for peptides with an ICK29,30.
Pn3a has on-target activity in DRG neurons and spinal slices
We assessed the effects of Pn3a on Na+ currents in acutely dissociated rat small-diameter dorsal root ganglion (DRG) neurons; in which NaV1.7 is the major TTX-sensitive channel24. Pn3a partially inhibited TTX-sensitive sodium current in small-diameter IB4− neurons (% inhibition: TTX (1 μM), 88 ± 3%; Pn3a (300 nM), 48 ± 5%), small-diameter lightly IB4+ neurons (% inhibition: TTX (1 μM), 76 ± 8%; Pn3a (300 nM), 34 ± 6%) and small-diameter strongly IB4+ neurons (% inhibition: TTX (1 μM), 21 ± 6%; Pn3a (300 nM), 11 ± 4%) neurons (Fig. 6a,b). The effect of Pn3a on TTX-sensitive current in large-diameter DRG neurons was less pronounced (% inhibition: TTX (1 μM), 81 ± 7%; Pn3a (300 nM), 13 ± 5%) (Fig. 6a,c).
We also assessed the effect of Pn3a on electrically evoked excitatory post-synaptic currents (eEPSCs) in neurons of the superficial dorsal horn. Pn3a (1 μM) significantly decreased C-fibre eEPSC amplitudes in lamina I neurons (% inhibition: 36.1 ± 4.6%; n = 7, P < 0.05; paired t-test). No significant decrease in eEPSC amplitudes was observed Aδ-fibres (% inhibition: 19.4 ± 6.4%; n = 7, P > 0.05; paired t-test) or Aβ-fibres (% inhibition: 8.7 ± 3.8%; n = 4, P > 0.05; paired t-test) (Fig. 6d,e).
Administration of selective NaV1.7 inhibitors alone does not produce analgesia
To assess the analgesic potential of selective NaV1.7 inhibition in vivo, we examined the effects of Pn3a, as well as the NaV1.7-selective small molecule inhibitor PF-04856264, in multiple rodent models of pain. To assess on-target activity at NaV1.7 in vivo, we assessed analgesic efficacy of Pn3a in a mouse model of NaV1.7-mediated pain based on intraplantar injection of the scorpion toxin OD1, which impairs inactivation and enhances persistent current produced by NaV1.719. Pn3a administered by intraperitoneal injection dose-dependently reduced OD1-induced spontaneous pain behaviours in the absence of adverse effects (pain behaviours/10 min: control, 112 ± 8; Pn3a (0.3 mg/kg), 76 ± 19; Pn3a (1 mg/kg), 37 ± 7; Pn3a (3 mg/kg), 22 ± 9; P < 0.05, one-way ANOVA; Fig. 7a), confirming on-target NaV1.7 activity in vivo. At the highest dose tested (3 mg/kg), analgesic activity persisted for at least 40 min, confirming Pn3a had a duration of action suitable for assessment in other pain models (Fig. 7b). We did not test PF-04856264, as efficacy in the OD1 model at a dose of 30 mg/kg was previously reported19.
We next tested Pn3a and PF-04856264 in mouse models of pain where genetic deletion of NaV1.7 attenuates or abolishes pain behaviours. Surprisingly, at doses that attenuated OD1-induced spontaneous pain, neither Pn3a or PF-04856264 reduced responses to noxious heat assessed by the hot plate test (time to withdrawal: control, 25.9 ± 1.8 s; Pn3a (3 mg/kg i.p.), 30.0 ± 3.1 s; PF-04856264 (30 mg/kg i.p.), 30.7 ± 3.8 s; P > 0.05, one-way ANOVA; Fig. 7c), despite noxious heat responses being abolished the NaV1.7Wnt knockout mouse31. In the formalin model, where genetic deletion of NaV1.7 attenuates formalin-induced spontaneous behaviours in both Phase I and Phase II31,32, neither Pn3a (3 mg/kg i.p.) (Fig. 7d) or PF-04856264 (30 mg/kg ip.) (Figure 7e) significantly reduced Phase I or Phase II pain behaviours (P > 0.05, two-way ANOVA). Similar results were found with carrageenan-induced inflammation, where thermal allodynia is abolished in the NaV1.7Nav1.8 knockouts33, but Pn3a and PF-04856264 had no significant anti-allodynic effect on mechanical thresholds (paw withdrawal force; PWF: control, 1.2 ± 0.2 g; Pn3a (3 mg/kg i.p.), 1.3 ± 0.4 g; PF-04856264 (30 mg/kg i.p.), 1.5 ± 0.3 g; P > 0.05, one-way ANOVA; Fig. 7f) or thermal thresholds (paw withdrawal temperature; PWT: control, 44.1 ± 0.5 °C; Pn3a (3 mg/kg i.p.), 45.0 ± 0.4 °C; PF-04856264 (30 mg/kg i.p.), 44.4 ± 1.2 °C; P > 0.05, one-way ANOVA; Fig. 7g).
As Pn3a and PF-04856264 are unlikely to cross the blood-brain barrier34, we also assessed if intrathecal administration of NaV1.7 inhibitors is required to elicit analgesia in Freund’s Complete Adjuvant (FCA)-induced inflammation, where mechanical and thermal allodynia are abolished in NaV1.7Nav1.8 knockouts33. Intrathecal Pn3a (0.3 nmoles) failed to reverse FCA-induced mechanical allodynia (PWF: control, 0.7 ± 0.2 g; Pn3a, 0.6 ± 0.1 g; P > 0.05; unpaired t-test; Fig. 7h) or thermal allodynia (time to withdrawal: control, 7.3 ± 1.8 s; Pn3a, 10.3 ± 0.8 s; P > 0.05; unpaired t-test; Fig. 7i) in rats. Notably, intrathecal Pn3a (0.3 nmoles) caused no motor adverse effects consistent with high NaV1.7 selectivity at this dose in vivo (Rotarod% Baseline: control, 88 ± 7%; Pn3a, 91 ± 11%; P > 0.05; unpaired t-test; Fig. 7j); however motor impairment was observed at a higher dose of 1 nmole (data not shown). Intrathecal PF-04856264 was not tested due to low potency at the rat NaV1.7 channel11.
Selective NaV1.7 inhibitors synergize with opioids to produce analgesia
Altered expression of endogenous opioid peptides was recently shown to contribute to the pain-free phenotype observed in humans and mice lacking NaV1.721. We therefore assessed the analgesic effects of the selective NaV1.7 inhibitors Pn3a and PF-04856264 in combination with subtherapeutic doses of the opioid oxycodone.
In the formalin model, administration of Pn3a with a subtherapeutic dose of oxycodone significantly reduced pain behaviours in Phase II only (pain behaviours: control, 227 ± 14; oxycodone (1 mg/kg i.p.), 231 ± 22; Pn3a (3 mg/kg i.p.), 185 ± 20; Pn3a (3 mg/kg i.p.) + oxycodone (1 mg/kg i.p.), 92 ± 15; P < 0.05, two-way ANOVA; Fig. 8a,b). Similar effects were seen in the carrageenan model, where administration of either Pn3a or PF-04856264 with a sub-therapeutic dose of oxycodone significantly increased mechanical thresholds (PWF: control, 1.2 ± 0.2 g; Pn3a (3 mg/kg i.p.), 1.3 ± 0.4 g; oxycodone (0.67 mg/kg i.p.), 1.8 ± 0.2 g; Pn3a (3 mg/kg i.p.) + oxycodone (0.67 mg/kg i.p.), 2.8 ± 0.4 g; PF-04856264 (30 mg/kg i.p.), 1.5 ± 0.3 g; PF-04856264 (30 mg/kg i.p.) + oxycodone (0.67 mg/kg i.p.), 3.5 ± 0.3 g; P < 0.05, one-way ANOVA; Fig. 8c) and thermal thresholds (PWT: control, 44.1 ± 0.5 °C; Pn3a (3 mg/kg i.p.), 45.0 ± 0.4 °C; oxycodone (0.67 mg/kg i.p.), 45.7 ± 0.8 °C; Pn3a (3 mg/kg i.p.) + oxycodone (0.67 mg/kg i.p.), 49.6 ± 0.6 °C; PF-04856264 (30 mg/kg i.p.), 44.4 ± 1.2 °C; PF-04856264 (30 mg/kg i.p.) + oxycodone (0.67 mg/kg i.p.), 50.4 ± 1.8 °C; P < 0.05, one-way ANOVA; Fig. 8d). Intraplantar administration of Pn3a (3 μM) with a sub-therapeutic dose of oxycodone did not result in analgesic synergy (PWF: 1.1 ± 0.1 g; PWT: 44.3 ± 0.6 °C). At these doses Pn3a alone or in combination with oxycodone had no significant effect on the parallel rod floor test (ataxia index: control, 3.7 ± 0.5; Pn3a, 4.3 ± 0.4; Pn3a + oxycodone, 4.2 ± 0.4; P > 0.05, one-way ANOVA), confirming the analgesic effects were not due to motor impairment.
To confirm the lack of efficacy wasn’t specific to Pn3a, we assessed another previously characterized spider peptide Nav1.7 inhibitor phlotoxin 120, and extended our assessment of opiate synergy to buprenorphine and the enkephalinase inhibitor thiorphan. Phlotoxin 1 (sequence ACLGQWDSCDPKASKCCPNYACEWKYPW CRYKLF) inhibits NaV1.7 with an IC50 of 260 nM but has no effect on other NaV isoforms at concentrations up to 2 μM20. Treating mice with phlotoxin 1 alone had little effect on acute heat pain-sensing responses measured with a Hargreaves apparatus. However, co-administration of phlotoxin 1 with thiorphan resulted in substantial analgesia (time to withdrawal: control, 5.7 ± 0.9 s; thiorphan (20 mg/kg i.p.), 5.0 ± 0.4 s; phlotoxin 1 (50 μg/kg i.p.), 7.3 ± 0.9 s; phlotoxin 1 (50 μg/kg i.p.) + thiorphan (20 mg/kg i.p.), 15.6 ± 2.5 s; P < 0.05, one-way ANOVA; Fig. 8e). Similar results were obtained when phlotoxin 1 was given in combination with the opioid agonist buprenorphine (time to withdrawal: control, 6.3 ± 0.5 s; buprenorphine (50 μg/kg i.p.), 7.2 ± 0.5 s; phlotoxin 1 (50 μg/kg i.p.), 5.8 ± 0.7 s; phlotoxin 1 (50 μg/kg i.p.) + buprenorphine (50 μg/kg i.p.), 21.0 ± 0.7 s; P < 0.05, one-way ANOVA; Fig. 8f), consistent with the data obtained with Pn3a. Next we assessed if the analgesic synergy was specific to opioids, or whether another clinically used analgesic, such as gabapentin, could also produce analgesia when given in combination with Pn3a. Administration of Pn3a with a subtherapeutic dose of gabapentin had no significant effect on carrageenan-induced mechanical allodynia (PWF: control, 1.1 ± 0.3 g; gabapentin (100 mg/kg i.p.), 1.1 ± 0.1 g; Pn3a (3 mg/kg i.p.) + gabapentin (100 mg/kg i.p.), 1.6 ± 0.2 g; P > 0.05, one-way ANOVA; Fig. 8g) or thermal allodynia (PWT: control, 44.5 ± 0.9 °C; gabapentin (100 mg/kg i.p.), 45.4 ± 0.5 °C; Pn3a (3 mg/kg i.p.) + gabapentin (100 mg/kg i.p.), 44.5 ± 1.2 °C; P > 0.05, one-way ANOVA; Fig. 8h).
Since loss-of-function mutations in SCN9A were first identified as the cause of CIP in 20064, there has been wide interest in the development of selective NaV1.7 inhibitors for treatment of pain35. However, due to high sequence homology between NaV1.1–1.9, development of highly selective NaV1.7 inhibitors has been challenging, making assessment of analgesic potential of truly selective NaV1.7 inhibition difficult to ascertain. In the search for novel NaV inhibitors, we screened spider venoms, a known rich source of disulfide-containing peptides with potential for subtype-selective activity at NaV channels, and subsequently identified Pn3a as a novel NaV1.7 subtype selective inhibitor.
Characterisation of Pn3a revealed it as one of the most potent and selective NaV1.7 inhibitors reported to date, with 40-fold selectivity over NaV1.1 and at least 100-fold selectivity over all other NaV subtypes. In comparison, ProTx-II, a spider peptide from the venom of Thrixopelma pruriens is at least 85-fold selective over NaV1.2–NaV1.823 while the aryl sulfonamide PF-04856264 binds to the slow inactivated state of NaV1.7 with at least 65-fold selectivity and the clinical lead PF-05089771 is only at least 10-fold selective19,24. While the required level of subtype-selectivity is difficult to estimate, assuming equivalent tissue penetrance and on-target activity and Hill slope of inhibition close to unity, 100-fold selectivity should enable complete NaV1.7 inhibition in the absence of marked effects on the function of other isoforms. High subtype-selectivity is important, since activity at other NaV isoforms, such as NaV1.6, likely contributes to analgesic activity but also adverse effects36,37,38.
NaV1.7 is expressed on sensory nerve endings in the skin, where it is thought to have a major role in regulating the excitability of peripheral sensory neurons39. The biophysical properties contributing to this specialized function include the slow closed-state inactivation that prevents NaV1.7 from inactivating during subthreshold depolarisations originating from transducer channels on sensory nerve endings in response to noxious stimuli. This enables NaV1.7 to amplify subthreshold depolarizations, or generator potentials, by producing ramp currents, which in turn cause sufficient membrane depolarization to activate NaV1.8, the major contributor to action potential electrogenesis in nociceptors40,41. Indeed, enhanced activation of NaV1.7 at peripheral nerve terminals, whether through toxins like OD1, or due to altered biophysical properties arising from gain-of-function mutations, undoubtedly leads to enhanced afferent firing and pain5,6,7,42. Thus, NaV1.7 at sensory nerve endings could be a key site of action for NaV1.7 inhibitors. Indeed, at the highest dose tested, Pn3a was able to significantly reduce spontaneous pain behaviours in mice caused by intraplantar injection of the NaV1.7 activator OD1, confirming on-target activity at NaV1.7 on sensory nerve endings in vivo. Although pain behaviours were not completely abolished, they were reduced to a similar level to those seen in NaV1.7 knockout mice, with residual pain responses likely attributable to NaV1.619.
In addition, Pn3a showed on-target activity on small-diameter DRG neurons, evidenced by inhibition of ~50% of TTX-sensitive current in both IB4+ and IB4− neurons, while TTX−sensitive currents remained largely unaffected in large DRG neurons. This is consistent with global NaV1.7 knockout mice, in which 37% of TTX-sensitive current is reduced in DRG neurons32. Interestingly, the majority of sodium current in small-diameter IB4+ neurons was TTX resistant, likely attributable to NaV1.943. However, despite clear inhibition of NaV1.7 in sensory neurons both in vitro and in vivo, neither Pn3a nor the aryl sulfonamide PF-04856264 produced analgesia in rodent models of acute nociception or inflammatory pain at doses sufficient to reduce OD1-induced spontaneous pain. While it is clear that enhanced activation of NaV1.7 at peripheral nerve terminals is sufficient to drive pain19, this lack of efficacy in animal models suggests that acute pharmacological inhibition of NaV1.7 at peripheral sensory nerve endings alone is not sufficient to elicit analgesia in these models. Five NaV subtypes are expressed on adult peripheral sensory neurons (NaV1.1, 1.6, 1.7, 1.8, 1.9), with C-fibres predominantly expressing NaV1.7 and the TTX-resistant subtypes NaV1.8 and NaV1.944,45,46. While it is thought that NaV1.7 plays a major role in setting the threshold of activation, NaV1.9 may also be involved in the production of ramp currents and amplification of generator potentials41. Indeed, in global NaV1.7 knockout mice, the receptive fields of C-fibres are still mechanically excitable32, suggesting that NaV1.7 channels on sensory nerve endings are not solely responsible for regulating action potential generation in all nociceptive neurons.
The spider peptide ProTx-II is also reported to lack analgesic activity in a rodent model of inflammatory pain, despite reaching plasma levels sufficient to inhibit NaV1.7 in vitro23. ProTx-II’s lack of analgesic activity was attributed to an inability to cross the blood-nerve-barrier, a sheath of connective tissue layers that encompasses the axons of peripheral nerves, and thus an inability to inhibit action potential propagation47. However, while NaV1.7 is expressed on axons, it is unlikely to have a major role in action potential propagation, given it has slow recovery from fast inactivation (repriming) compared to other NaV subtypes, such as NaV1.6 and NaV1.8, which can sustain repetitive firing39,48,49.
NaV1.7 is also expressed on the central projections of DRG neurons in the superficial laminae I and II of the spinal cord, localised on the pre-synaptic terminals, where it is thought to be important in the regulation of neurotransmitter release24,31,39. As the physicochemical properties of spider peptides generally preclude crossing of the blood-brain barrier, we assessed if NaV1.7 inhibition at the level of the spinal cord is required to produce analgesia by administering Pn3a intrathecally. Despite reducing C-fibre evoked eEPSC amplitudes in lamina I neurons by 36%, intrathecal Pn3a at the highest tolerated dose had no analgesic activity in vivo. This therefore suggests that a greater level of eEPSC amplitude inhibition is required to translate to analgesia in vivo. While it is unclear what level of NaV1.7 inhibition Pn3a achieved when delivered by the intrathecal route, it is clear it was active in vivo by the occurrence of motor adverse effects at the highest dose tested.
Pn3a inhibits NaV1.7 by decreasing peak current and shifting the voltage-dependence of activation to more depolarized potentials; however, current is not completely inhibited at all membrane potentials. While most mutations associated with CIP lead to a complete loss of NaV1.7 function, it is unclear what level of pharmacological inhibition is required to recapitulate a pain-free phenotype. Dynamic clamp experiments in small DRG neurons suggest that total loss of Nav1.7 should increase current threshold for single action potentials by about 40%, together with a marked decrease in ability to produce repetitive impulse activity50. Two mutations (W1775R and L1831X) have been identified in CIP patients that retain NaV1.7 function, but cause a voltage-dependent depolarizing shift in channel activation, similar to Pn3a51. This suggests that a high level of, but not complete, inhibition is sufficient to cause analgesia. However, it should be noted that these mutations would be associated with substantial loss of NaV1.7 current at central and peripheral sites. It is plausible that this is not achievable with peptidic inhibitors or small molecule inhibitors such as the aryl sulfonamides which penetrate the blood-brain barrier poorly. Thus, our data support evidence from genetic studies suggesting that substantial reduction of NaV1.7 current is required for analgesia.
Although Pn3a was able to almost completely reverse OD1-induced pain behaviours, this may represent a specialised case, with the apparent analgesic effect arising from concentration-dependent normalisation of NaV1.7 function. Consistent with this notion, intraperitoneal injection of Pn3a produced reversal of OD1-induced pain behaviours in a dose-dependent manner. In contrast, antinociception in naïve animals, or the inflammatory models assessed here, may require complete or near complete inhibition of NaV1.7 at all peripheral and central sites. It thus remains to be determined whether incomplete NaV1.7 inhibition will lead to partial analgesia in conditions such as IEM, where exaggerated pain develops from enhanced NaV1.7 function.
Thus, the most likely explanation for the lack of efficacy of Pn3a remains the lack of sufficient inhibition of NaV1.7, rather than a requirement for a concomitant opioid activation.
In this study, the selective NaV1.7 inhibitors Pn3a, PF-04856264 and phlotoxin 1 were administered once as a single dose. It is unclear if repeated administration or chronic administration of NaV1.7 inhibitors is required to elicit analgesia. While limited material and poor pharmacokinetics precluded testing Pn3a chronically, it is interesting to note that the pain-free phenotype develops over several days in inducible NaV1.7 knockout mice52. While this could reflect slow turn-over of NaV1.7, an alternative explanation could be that analgesia emerges in parallel with upregulation of the endogenous opioid precursor proenkephalin (Penk), an effect unlikely to be reproduced with single administration of a NaV1.7 inhibitor with a relatively short duration of action21.
In further support of an important link between NaV1.7 and opioids, we were able to produce analgesia by administering the selective NaV1.7 inhibitors Pn3a, PF-04856264 and phlotoxin 1 in combination with a sub-effective dose of the clinically used opioids oxycodone or buprenorphine or the enkephalinase inhibitor thiorphan, but not with the calcium channel inhibitor gabapentin. While these data clearly demonstrate that analgesic synergy between NaV1.7 inhibitors and opioids is not restricted to a single agent or single pharmacological class, the mechanisms underlying synergistic analgesia remain unclear. Interestingly, the opioid antagonist naloxone substantially reverses analgesia in both mice and human lacking functional NaV1.721. In the transcriptome of sensory neurons from Advillin-Cre NaV1.7 knockout mice, no changes in endogenous opioid receptor transcripts were reported, only upregulation of Penk mRNA and Met-Enkephalin protein21. It therefore appears that NaV1.7 inhibition in combination with opioid receptor activation, whether through upregulation of endogenous opioids, such as the enkephalins as demonstrated in the knockout experiments, or administration of exogenous opioids, as described here, can elicit profound analgesia53. Opioid receptors are expressed on peripheral sensory neurons, both on the peripheral and central projections, as well as along the axon, where they are involved in regulating neuronal excitability, action potential propagation, and neurotransmitter release through inhibition of calcium currents54,55. Thus, the synergistic activity of opioid receptor agonists with selective NaV1.7 inhibitors may involve both central and/or peripheral opioid effects. Interestingly, analgesic synergy between oxycodone and Pn3a was not observed after intraplantar administration, suggesting that inhibition of NaV1.7 at the receptive fields does not contribute to the synergistic effect observed after systemic dosing.
In summary, based on its exquisite selectivity, Pn3a is a useful pharmacological tool to probe the role of NaV1.7 inhibition in pain. While efficacy in the OD1 model, as well as emerging positive clinical trial results with small molecule aryl sulfonamides56, suggest that NaV1.7 inhibitors may be efficacious in IEM or PEPD, our results reveal that acute administration of peripherally restricted NaV1.7 inhibitors alone may not have broad efficacy in inflammatory pain. The efficacy of peripherally restricted NaV1.7 inhibitors in other pain types, such as neuropathic pain, remains to be determined, and underscores the need for further studies to determine how, or whether, Nav1.7 blockade will reduce pain in humans. Our results do highlight that the combination of NaV1.7 inhibitors and opioids may provide a novel therapeutic approach for the treatment of pain.
Isolation of Pn3a
Crude venom was isolated from a single specimen of Pamphobeteus nigricolor by electrostimulation as previously described57. Crude venom (1 mg) was dissolved in 5% acetonitrile (ACN)/0.1% formic acid and loaded onto an analytical C18 reversed-phase (RP) HPLC column (Vydac 4.6 × 250 mm, 5 μm; Grace, Columbia, MD, USA) attached to an UltiMate 3000 HPLC system (Dionex, Sunnyvale, CA, USA). Components were eluted at 0.7 mL/min and collected into 1 min fractions with solvent A (99.9% H2O, 0.1% formic acid) and solvent B (90% ACN, 0.1% formic acid in H2O) using the following gradient: 5% solvent B over 5 min, followed by 5–50% solvent B over 45 min followed by 50–100% solvent B over 15 min.
Venom fractions were assessed for activity at rNaV1.3 stably expressed in HEK293 cells using a FLIPRTETRA (Molecular Devices) membrane potential assay as previously described58. Active fractions were further fractionated to near-purity and peptide masses were determined using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS using a Model 4700 Proteomics Analyser (Applied Biosystems, Foster City, CA, USA) by spotting HPLC fractions with α-cyano-4-hydroxycinnamic acid (7 mg/mL in 50% ACN). Peptides were then reduced and alkylated and N-terminal sequence determination was performed by the Australian Proteome Analysis Facility (Macquarie University, NSW, Australia).
Synthesis of Pn3a
μ-TRTX-Pn3a was assembled on a Symphony authomated peptide synthesiser (Protein Technologies Inc., Tucson, AZ, USA) peptide synthesiser using a H-Thr(tBu)-2-ClTrt polystyrene resin (loading 0.67 mmol/g) on a 0.1 mmol scale. Fmoc deprotection was achieved using 30% piperidine/N, N-dimethylformamide (DMF) (1 × 1.5 min, then 1 × 4 min). Couplings were performed in DMF using 5 equivalents of Fmoc-amino acid/HBTU/DIEA (1:1:1) relative to resin loading for 2 × 20 min. Amino acid side-chains were protected as Asp(OtBu), Arg(Pbf), Cys(Trt), Glu(OtBu), His(Trt), Lys(Boc), Thr(tBu), Trp(Boc), Tyr(tBu). Cleavage from the resin and removal of side-chain protecting groups was achieved by treatment with 95% TFA/2.5% triisopropylsilane (TIPS)/2.5% H2O at room temperature for 2 h. After most of the cleavage solution was evaporated under a stream of N2, the product was precipitated and washed with cold diethyl ether and lyophilised from 50% ACN/0.1% TFA/H2O. Oxidative folding was carried out in the presence of oxidized and reduced glutathione at 4 °C and the single major product was isolated by preparative RP-HPLC.
HEK293 cells heterologously expressing human NaV1.1–1.7 (SB Drug Discovery, Glasgow, UK) were cultured in MEM containing 10% v/v FBS and selection antibiotics as recommended by the manufacturer. CHO cells stably expressing human NaV1.8 in a tetracycline-inducible system (ChanTest, Cleveland, OH) were cultured in Ham’s F-12 containing 10% (v/v) FBS and selection antibiotics as recommended by the manufacturer. To induce hNaV1.8 expression, cells were cultured in the presence of tetracycline (1 μg/ml) for 24 h at 27 °C. HEK293 cells expressing rNaV1.359 or rNaV1.748 were cultured in DMEM containing 10% v/v FBS and the selection antibiotic G-418 (0.5 mg/mL). SH-SY5Y human neuroblastoma cells were cultured in RPMI containing 15% FBS and supplemented with L-glutamine. Cells were grown in a humidified 5% CO2 incubator at 37 °C, grown to 70–80% confluence, and passaged every 3–4 days using TrypLE Express (Invitrogen). HEK293 cells heterologously expressing human NaV1.9, mouse NaV1.7 or hNaV1.7 M123 mutant (Y1537S/W1538R/D1586E)11 were generated and cultured by Icagen Inc (Durham, NC, USA).
Calcium responses in SH-SY5Y cells
To assess activity at CaV1.3, CaV2.2, α3-containing and homopentameric α7 nAChR endogenously expressed in SH-SY5Y human neuroblastoma cells, the effect of Pn3a on Ca2+ responses was assessed using a FLIPRTetra assay as described60. In brief, SH-SY5Y cells plated at a density of 50,000 cells/well on black-walled 384-well imaging plates were loaded with Calcium 4 no-wash dye (Molecular Devices) for 30 min after 48 h in culture. After 5 min pre-treatment with Pn3a (0.1–10 μM), responses were elicited by stimulation with KCl (90 mM)/CaCl2 (5 mM) in the presence of ω-conotoxin CVID (10 μM; CaV1.3); KCl (90 mM)/CaCl2 (5 mM) in the presence of nifedipine (10 μM; CaV2.2); nicotine (30 μM, α3-containing nAChR) or choline (30 μM) in the presence of PNU120596 (α7 nAChR). Fluorescence responses were normalized to baseline and the maximum increase in fluorescence determined using ScreenWorks 22.214.171.124 (Molecular Devices).
Whole-cell patch-clamp electrophysiology
For hNaV1.1–1.8 and rNaV1.7, whole-cell patch-clamp experiments were performed on a QPatch-16 automated electrophysiology platform (Sophion Bioscience, Ballerup, Denmark) as described61. The extracellular solution contained in mM: NaCl 145, KCl 4, CaCl2 2, MgCl2 1, HEPES 10 and glucose 10; pH 7.4; osmolarity 305 mOsm. The intracellular solution contained in mM: CsF 140, EGTA/CsOH 1/5, HEPES 10 and NaCl 10; pH 7.3 with CsOH; osmolarity 320 mOsm. Pn3a was diluted in extracellular solution with 0.1% BSA at the concentrations stated. All Pn3a effects were compared to pre-toxin control parameters within the same cell, and incubation times were varied between 5 and 40 min depending on the time required for steady-state inhibition to be achieved.
Concentration-response curves were obtained with a holding potential of −80 mV followed by a pre-pulse of −120 mV for 100 ms and then a 20 ms test pulse of −20 mV for NaV1.1−1.7 and +10 mV for NaV1.8 (repetition interval 20 s). I-V curves were obtained with a holding potential of −80 mV followed by a pre-pulse of −100 mV for 50 ms and a series of 50 ms step pulses that ranged from −80 to +60 mV in 5-mV increments before returning to a holding potential of −80 mV (repetition interval 5 s). Conductance-voltage curves were obtained by calculating the conductance (G) at each voltage (V) using the equation G = I/(V − Vrev), where Vrev is the reversal potential and were fitted with a Boltzmann equation. Voltage dependence of steady-state fast inactivation was measured using a series of 500 ms pre-pulses, ranging from −120 to −10 mV in 10-mV increments, followed by a 20 ms pulse of −20 mV for NaV1.1–1.7 and +10 mV for NaV1.8 to assess the available non-inactivated channels (repetition interval 30 s). Time-to-peak was measured from pulse onset to maximal current and fast inactivation time constants were calculated by fitting current decay traces with a single exponential function using the I-V protocol described above. Recovery from fast inactivation was examined using a two-pulse protocol consisting of a depolarizing pulse to 0 mV for 200 ms to inactivate channels, followed by a step to −90 mV of variable duration (1–90 ms) to promote recovery, and a 20 ms test pulse to 0 mV to assess availability of channels. Voltage dependence of steady-state slow inactivation was measured using a series of 15 s pre-pulses, ranging from −100 to −20 mV in 10-mV increments, followed by a 50 ms step to −100 mV to remove fast inactivation, and a 50 ms test pulse to 0 mV to assess the available non-inactivated channels (repetition interval 30 s). Ramp currents were evoked by a depolarization from a holding potential of −100 to +20 mV at a rate of 2.4 mV/ms.
For hNaV1.9, mNaV1.7 and hNaV1.7 M123 mutant, whole-cell patch-clamp experiments were performed by Icagen Inc on a PatchXpress automated electrophysiology platform (Molecular Devices, Sunnyvale, CA, USA). The extracellular solution contained in mM: NaCl 135, KCl 5.4, CaCl2 2, MgCl2 1, HEPES 10 and glucose 5; pH 7.4; osmolarity 300 mOsm. The intracellular solution contained in mM: CsF 135, EGTA 5, CsCl 10, HEPES 10 and NaCl 5; pH 7.4; osmolarity 298 mOsm. For hNaV1.9, concentration-response curves were obtained with a holding potential of −140 mV followed by a 40 ms test pulse of −40 mV (repetition interval 20 s). For mNaV1.7 and hNaV1.7 M123 mutant, concentration-response curves were obtained with a holding potential of −120 mV followed by a 20 ms test pulse of 0 mV (repetition interval 10 s).
hNav1.7/rKv2.1 chimeras and electrophysiology
hNav1.7/rKv2.1 chimeras containing the S3–S4 paddle regions of the four domains of hNav1.7 were described previously26. hNav1.7/rKv2.1 chimera or rKv2.1 cDNA was injected into Xenopus laevis oocytes, which were then held at 17 °C in ND96 solution (in mM: 96 NaCl, 2 KCl, 5 HEPES, 1 MgCl2, 1.8 CaCl2 and 50 μg·mL−1 gentamycin, pH 7.6) for 2–4 days before experiments. Currents were measured using two-electrode voltage-clamp electrophysiology (Axoclamp 900 A, Molecular Devices, Sunnyvale, CA, USA; 40 μL recording chamber). Micro-electrodes were filled with 3 M KCl and had resistances of 0.3–1 MΩ. Data were filtered at 4 kHz and digitized at 20 kHz using pClamp software (Molecular Devices). The external recording solution contained (in mM) 50 KCl, 50 NaCl, 5 HEPES, 1 MgCl2, 0.3 CaCl2, pH 7.6 with NaOH, and recordings were performed at room temperature (22 °C). Pn3a (300 nM) was diluted in external recording solution with 0.1% BSA. Currents were elicited by depolarisation to +70 mV from a holding potential of −90 mV (−120 mV for DIII), with a tail voltage at −60 mV (−90 mV for DIII).
NMR structure determination
All NMR spectroscopy experiments were performed on a Bruker Avance 600 MHz spectrometer equipped with a cryoprobe. Samples for NMR spectroscopy were prepared by dissolving peptide in either 90% H2O/10% D2O or 100% D2O at pH of 4.0 to a final concentration of 2 mg/mL. Homonuclear 1H-1H TOCSY, NOESY and E.COSY, as well as heteronuclear natural abundance 1H-15N HSQC, and 1H-13C HSQC spectra were all recorded at 25 °C.
Following resonance assignments the NOESY spectra were assigned automatically using CYANA, and preliminary structures calculated using torsion angle dynamics62. Backbone and side chain dihedral angles restraints were determined from TALOS-N63. 1H-1H TOCSY spectra were recorded at temperatures of 15–35 °C to calculate amide temperature coefficients. Backbone amide protons that showed both slow solvent exchange in 100% D2O and had a chemical shift temperature dependence of more than −0.0046 parts per million (ppm)/K were considered to be definitively hydrogen bonded64, and included as restraints. Final structures were calculated using water refinement within the CNS program28. The final ensemble of 20 structures was chosen based on final energies and stereochemistry as assessed by MolProbity65. Structures were visualized using MolMol65,66.
DRG preparation and electrophysiology
Spinal level L3–L5 DRGs were removed from male Sprague–Dawley rats (aged 3–6 weeks) and placed in ice-cold HEPES-buffered saline (HBS) composed of (in mM): 154 NaCl, 2.5 KCl, 1.8 CaCl2, 1.5 MgCl2, 10 HEPES, and 10 glucose (pH 7.4, 330 ± 5 mOsm). DRG cells were then prepared as described previously67. To visualize IB4 binding, isolated DRG cells were pre-treated with 1 μg/mL Alexa Fluor 488-conjugated Bandeiraea simplicifolia IB4 (Invitrogen) for 5 min at room temperature and washed with HBS for 5 min before fluorescence was examined on the inverted microscope (Olympus, IX50) used for patch-clamp recordings. Cell diameter was determined using a micrometer graticule: <25 μm was defined as small-diameter and >25 μm was defined as large-diameter.
Whole-cell patch clamp recordings were performed at room temperature (22–24 °C) using an EPC-9 patch-clamp amplifier and corresponding PULSE software from HEKA Electronik (Lambrecht/Pfalz, Germany) or an Axopatch ID amplifier (Axon Instruments, Foster City, CA, USA) using pCLAMP acquisition software (v. 5.5, Axon Instruments). Currents were sampled at 50 kHz. Patch pipettes were pulled from borosilicate glass (AM Systems, Everett, WA, USA) and pipette input resistance was 2–3 MΩ. The capacitance of individual cells ranged between 5 and 60 pF with a series resistance between 1 and 9 MΩ. Series resistance compensation of at least 80% was used in all experiments. Capacitance transients were compensated automatically using a built-in procedure of the HEKA amplifier. Leak current was subtracted online using a P/6 protocol. The liquid junction potential was 9 mV.
To isolate INa, the extracellular solution contained (in mM): 110 tetraethylammonium chloride (TEACl), 30 NaCl, 2.5 KCl, 1.8 CaCl2, 1.2 MgCl2, 10 HEPES, 10 glucose, 0.1 CdCl2; pH 7.4; 330 ± 5 mOsm with 0.1% BSA and the intracellular pipette solution contained (in mM): 120 CsCl, 10 HEPES, 10 EGTA, 2 CaCl2, 5 MgATP, 5 Na2GTP, 5 NaCl; pH 7.3; 285 ± 5 mOsm. Peak INa was determined by stepping the membrane potential from a holding potential of −80 mV to 0 mV for 10 ms every 10 s. Cells were perfused with TTX (1 μM) and Pn3a (300 nM) via a pressure driven perfusion system (AutoMate Scientific). All Pn3a effects were compared to pre-toxin control parameters within the same cell.
Spinal cord slice preparation and electrophysiology
Male Sprague-Dawley rats (aged 5–7 weeks) were anaesthetized with isoflurane, decapitated and the lumbar region of the spinal cord was removed. Parasagittal slices (440 μm thick) of spinal cord with dorsal roots intact were prepared as described previously68. Slices were transferred to a recording chamber and superfused continuously at 2 ml/min with normal artificial cerebro-spinal fluid (ACSF) composed of (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 1.2 MgCl2, 2.5 CaCl2, 25 glucose, and 11 NaHCO3; that had been equilibrated with 95% O2 and 5% CO2 and recordings were performed at room temperature. Dodt-contrast optics was used to identify lamina I neurons in the superficial dorsal horn. A Cs+-based internal solution, which should minimise postsynaptic effects, was used to record electrically evoked eEPSCs and contained (in mM): 140 CsCl, 10 EGTA, 5 HEPES, 2 CaCl2, 2 MgATP, 0.3 NaGTP, 5 QX-314.Cl, and 0.1% biocytin (osmolarity 285–295 mOsm). Patch electrodes had resistances between 3 and 5 MΩ. Synaptic currents were measured in whole-cell voltage-clamp (−70 mV, not corrected for a liquid junction potential of 4 mV) from lamina I cells. Bipolar tungsten electrodes placed at the end of the dorsal root (≥5 mm from the entry zone) were used to elicit eEPSCs. Prior to the start of each experiment, protocols with trains of stimuli at 1 Hz, 2 Hz and 20 Hz were used to determine the presence and onset latency of C, Aδ and Aβ currents, respectively. In four experiments, strychnine (0.3 μM) was added to the ACSF to increase the likelihood of neurons with Aβ currents. Recordings were performed on neurons before and after perfusion with Pn3a (1 μM).
For behavioural assessment we used adult male C57BL/6 J mice or Sprague Dawley rats aged 5–8 weeks. Animals were housed in groups of 2–4 per cage, under 12 h light-dark cycles with standard rodent chow and water ad libitum. All assessments were performed by a blinded investigator unaware of the treatment each animal received. Ethical approval for in vivo experiments in animals was obtained from the University of Queensland, University of Sydney or United Kingdom Home Office animal ethics committee. Experiments involving animals were conducted in accordance with the International Association for the Study of Pain Guidelines for the Use of Animals in Research and the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 8th edition (2013).
The NaV1.7 activator OD1 (300 nM) was administered by intraplantar (i.pl) injection in mice as previously described19. Pn3a (0.3, 1, 3 mg/kg) was diluted in saline and pre-administered 10 min prior by intraperitoneal (i.p.) injection. Spontaneous pain behaviours were counted by a blinded observer from video recordings.
Acute Heat Responses
Mice, pre-administered Pn3a (i.p. 3 mg/kg) or PF-04856264 (i.p. 30 mg/kg), were placed on a temperature-controlled Peltier plate (Hot/Cold Plate, Ugo Basile, Comerio, Italy) set at 50 °C, and the time taken to observe a nociceptive response (hind paw lick, flinch or jump) was recorded. Paw-withdrawal latency in mice pre-administered phlotoxin 1 (i.p. 50 μg/kg; Venomtech, Valbonne, France), thiorphan (i.p. 20 mg/kg), buprenorphine (i.p. 50 μg/kg), or combinations, was determined using the Hargreaves apparatus (Plantar Analgesia Meter, IITC, CA, USA), with three withdrawal responses measured per animal.
Formalin (1% v/v) was administered by i.pl injection in mice as previously described61. Pn3a (i.p. 3 mg/kg), oxycodone (i.p. 1 mg/kg), alone or in combination, were diluted in saline and administered at the same time as formalin. Spontaneous pain behaviours were counted from video recordings. Phase I was defined as 0–10 min and Phase II defined as 10–55 min following formalin injection.
Carrageenan (1% w/v) was administered by i.pl injection in mice as previously described42. Behavioural assessment was performed 3 h post-injection. Pn3a (i.p. 3 mg/kg), PF-04856264 (i.p. 30 mg/kg), oxycodone (i.p. 0.67 mg/kg), gabapentin (i.p. 100 mg/kg) or the combination thereof, were administered 10 min prior to behavioural assessment. Mechanical thresholds were determined using electronic von Frey (MouseMet Electronic von Frey, TopCat Metrology, UK) as previously described42. Thermal thresholds were determined using the thermal probe test (MouseMet Thermal, TopCat Metrology) as described42.
Freund’s Complete Adjuvant
FCA was administered undiluted in a volume of 150 μL by i.pl injection in rats. Behavioural assessment was performed 3 days post-injection of FCA. For intrathecal administration, a polyethylene lumbar catheter was inserted into the intrathecal space between vertebrae L4–L5. Pn3a (0.3 nmoles) was diluted in saline and administered by intrathecal injection in a volume of 10 μL 30 min prior to behavioural assessment. Mechanical paw withdrawal thresholds were determined using manual von Frey with a series of calibrated filaments 0.4–15.1 g (Stoelting Co., Wood Dale, USA) using the up-down method69. Paw withdrawal latency to a thermal stimulus was determined using the Hargreaves test (Ugo Basile, Camerio VA, Italy). Motor co-ordination was assessed using an accelerating rotarod (Ugo Basile). Latency to fall was recorded in seconds, with a maximal cut off of 300 s. At the completion of experiments, catheter placement was checked by injection of lignocaine (2%, 10 μL) and observation of rapid bilateral hind limb paralysis.
Parallel Rod Floor Test
Motor performance in mice was assessed using the Parallel Rod Floor Test and analysed using ANY-Maze software (Stoelting Co) as described19. Pn3a (3 mg/kg), alone or in combination with oxycodone (0.67 mg/kg), was administered by the i.p. route as described above 15 min prior to assessment of motor performance. The ataxia index was calculated by dividing the number of foot slips by the distance travelled (m).
Data were plotted and analyzed using GraphPad Prism, version 6.0. For concentration-response curves, a four-parameter Hill equation with variable Hill coefficient was fitted to the data. IC50 values are mean ± SEM of the negative logIC50 (pIC50). Statistical significance was defined as P < 0.05 and was determined by an paired t-test assuming equal variance, or one-way ANOVA with Dunnett’s post-test, or two-way ANOVA with Dunnett’s or Sidak’s post-test, as appropriate. Data are presented as mean ± SEM.
How to cite this article: Deuis, J. R. et al. Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a. Sci. Rep. 7, 40883; doi: 10.1038/srep40883 (2017).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This study was supported by grants from the Australian National Health and Medical Research Council (Project grant APP1102267, Program Grant APP1072113, Senior Principal Research Fellowship to M.J.C. and Principal Research Fellowships to P.F.A., G.F.K., and R.J.L.) and a Pharmaceutical Society of Australia Early Career Research Grant (I.V.) I.V. is supported by an Australian Research Council Future Fellowship. S.G.W. and S.D.D-H. were supported by grants from the Department of Veterans Affairs. We thank Bastian Rast (Switzerland) for providing Pamphobeteus nigricolor for venom extraction. This research was facilitated by access to the Australian Proteome Analysis Facility supported under the Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS).
About this article